Reshaping the future of myopia – A new management guide

Johnson & Johnson Vision, the American Optometric Association, the Singapore Optometric Association, and the American Academy of Optometry have partnered to create Managing Myopia: A Clinical Response to the Growing Epidemic, a guide to support eye care professionals in managing myopia in patients, launching in two 1-hour live stream events.

Reshaping the future of myopia
– A new management guide

Managing Myopia: A Clinical Response to the Growing Epidemic

Intended to provide guidance to eye care practitioners in the management of myopia in clinical practice, this guide has been created in collaboration with the American Optometric Association, the Singapore Optometric Association, the American Academy of Optometry, and Johnson & Johnson Vision and is informed by currently available scientific research.

Kids move fast.
Myopia does too.

The rate of myopia prevalence has doubled over the past 20 years, and by 2050 half of the world's population is projected to be myopic.1 So how can we slow its progression? Johnson & Johnson Vision is collaboratively advancing the next generation of science, researching and developing new solutions with the potential to transform the standards of care in myopia, and changing the trajectory of eye health.

Meet the live speakers

We are proud to partner with these distinguished individuals to help educate eye care professionals about myopia, the greatest eye health threat of the 21st century.

David Berntsen, OD, PhD, FAAO

American Academy of Optometry

Noel Brennan, MScOptom, PhD, FAAO

Clinical Research Fellow, Myopia Control Platform Johnson & Johnson Vision

Robert C. Layman, OD

President-Elect American Optometric Association

Kathryn Richdale, OD, PhD, FAAO

Associate Professor, University of Houston

Ken Tong, BSc Optom

President Singapore Optometric Association
Share this event with a colleague!

Reshaping the Future of Myopia –
A New Management Guide

Don't miss out! Join hundreds of other eye care professionals and myopia experts.

Three Universal Truths About Myopia

1 .

Myopia is chronic and progressive2.

Myopia is a chronic, progressive disease characterized by excessive eye elongation, risk of associated sight-threatening complications, and a negative-powered refractive error.

2 .

Myopia is a growing epidemic3.

Reports of increased myopia prevalence in Taiwan, Singapore, and Hong Kong emerged in the 1980s, and rates have continued to rise worldwide4. Those in the first wave of increased prevalence are on the cusp of experiencing sight-threatening complications.

3 .

All children should be monitored.

There is no safe level of myopia5. From an early age, measuring and monitoring both axial length and refractive error is highly recommended in all myopic children with even moderate risk of myopia progression.

Measurement of axial length is the preferred method for monitoring myopia progression over refractive error because of the strong association between eye length and risk of developing complications. Treatment efficacy should be measured with Cumulative Absolute Reduction in axial Elongation (CARE)6.

1. Holden et al Ophthalmol 2016; 123: 1036
2. JJV data on file;
3. Vitale et al., Increased prevalence of Myopia in the United States between 1971-1972 and 1999-2004. Arch Ophthalmol 2009;127:1632;
4. Ding et al., Myopia among schoolchildren in East Asia and Singapore. Surv Ophthalmol. 2017;62: 677;
5. Flitcroft. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res. 2012;31:622;
6. Bullimore et al. A gold standard for myopia control efficacy: Cumulative Absolute Reduction of axial Elongation (CARE). International Myopia Conference, Tokyo September 2019. O-056.

Learn how Johnson & Johnson Vision is working to address the myopia epidemic

Reshaping The Future of Myopia – A New
Management Guide